Pancreatic Cancer Research

ResearcherErasmus MCActive in the last 2 years

Gaby J. Strijk

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-8916-2300; OpenAlex author ID A5001944120. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
45
Papers, trials and grants by year

2023: 1 paper · 2024: 3 papers · 2025: 1 paper · 2026: 3 papers

Papers 8

  1. The value of FOLFIRINOX in advanced pancreatic cancer: balancing efficacy, toxicity, and quality of life. Co-author DOI 10.1007/s00520-026-10568-3↗
  2. Bulk RNA sequencing deconvolution of early-onset pancreatic ductal adenocarcinoma identifies cancer-associated fibroblast subsets associated with survival and … Co-author DOI 10.1016/j.ctarc.2026.101490↗
  3. Pancreatic Ductal Adenocarcinoma with Atypical Genomic Profile: A Case of Long-Term Survival with KRAS-Wildtype, Microsatellite Instability and High Tumor Muta… Co-author DOI 10.1159/000552404↗
  4. Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study. Co-author DOI 10.1016/j.ejca.2025.116065↗
  5. FOLFIRINOX chemotherapy modulates the peripheral immune landscape in pancreatic cancer: Implications for combination therapies and early response prediction. First author DOI 10.1016/j.ejca.2023.113440↗
  6. A liquid biomarker signature of inflammatory proteins accurately predicts early pancreatic cancer progression during FOLFIRINOX chemotherapy. Co-author DOI 10.1016/j.neo.2024.100975↗
  7. HLA-A*02:01allele is associated with decreased risk and a longer survival in pancreatic cancer: Results from an exhaustive analysis of theHLAvariation in PDAC Co-author DOI 10.1101/2024.08.29.24312704↗
  8. Analyzing Flow Cytometry or Targeted Gene Expression Data Influences Clinical Discoveries-Profiling Blood Samples of Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.3390/cancers15174349↗

Closest collaborators

The 25 strongest of 45 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Casper H.J. van Eijck · 8 shared papers, 2023–2026 · strength 1.91
  2. Casper W.F. van Eijck · 4 shared papers, 2023–2026 · strength 0.92
  3. Johanna W. Wilmink · 3 shared papers, 2025–2026 · strength 0.85
  4. Willem de Koning · 3 shared papers, 2023–2026 · strength 0.69
  5. Dana A. M. Mustafa · 3 shared papers, 2023–2024 · strength 0.63
  6. Michail Doukas · 2 shared papers, 2025–2026 · strength 0.56
  7. Judith de Vos‐Geelen · 2 shared papers, 2025–2026 · strength 0.49
  8. Marjolein Y.V. Homs · 2 shared papers, 2025–2026 · strength 0.49
  9. Bas Groot Koerkamp · 2 shared papers, 2024–2025 · strength 0.43
  10. Fleur van der Sijde · 2 shared papers, 2023–2024 · strength 0.40
  11. Núria Malats Riera · 2 shared papers, 2024 · strength 0.36
  12. Lukas J.A.C. Hawinkels · 1 shared paper, 2026 · strength 0.30
  13. Bram W. van Os · 1 shared paper, 2026 · strength 0.30
  14. Nicole Dam · 1 shared paper, 2026 · strength 0.30
  15. Vera Kemp · 1 shared paper, 2026 · strength 0.30
  16. Anne Margarethe Stiggelbout · 1 shared paper, 2026 · strength 0.29
  17. Brigitte C.M. Haberkorn · 1 shared paper, 2026 · strength 0.29
  18. Aniek E. van Diepen · 1 shared paper, 2026 · strength 0.29
  19. Eveline E. Vietsch · 1 shared paper, 2024 · strength 0.21
  20. Marcella Willemsen · 1 shared paper, 2024 · strength 0.21
  21. Jelle C. van Dongen · 1 shared paper, 2025 · strength 0.20
  22. Ignace H. J. T. de Hingh · 1 shared paper, 2025 · strength 0.20
  23. Nigel G. Kooreman · 1 shared paper, 2025 · strength 0.20
  24. Lodewijk A.A. Brosens · 1 shared paper, 2025 · strength 0.20
  25. Raúl Rabadán · 1 shared paper, 2024 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.